The 9C10 (MFR4.B) monoclonal antibody specifically binds to the Integrin α4 chain (CD49d), which is expressed as a heterodimer with either of two β chains, β1 or β7. The α4β1 integrin (VLA-4, CD49d/CD29) is expressed on most peripheral lymphocytes, thymocytes, and monocytes; while the α4β7 integrin (LPAM-1) is expressed on peripheral lymphocytes, but on only a small subset of thymocytes. These integrins mediate a variety of cell-cell and cell-matrix interactions, recognizing the ligands VCAM-1 (CD106) and fibronectin. Integrin α4β7 also preferentially binds to the mucosal vascular addressin, MAdCAM-1. Although the 9C10 (MFR4.B) antibody alone has been reported to have little function-blocking activity, it can augment the inhibitory effects of mAb R1-2 (Cat. No. 553153), resulting in almost complete inhibition of VLA-4 binding to VCAM-1.
This antibody is routinely tested by flow cytometric analysis. Other applications were tested at BD Biosciences Pharmingen during antibody development only or reported in the literature.